important fetal hemoglobin biomarker in baboons, confirming the
product's ability to activate a specific silenced gene (Abstract 571).
An oral presentation by Donald Lavelle, Ph.D., of the University of
Illinois at Chicago, provided evidence that S110 increases fetal
hemoglobin and decreases DNA methylation in non-human primates and
cultured human erythroid progenitor cells (Poster 779). Finally the
prevention of cancer cell proliferation in non-clinical models, by the
Company's lead JAK2 kinase inhibitors was presented (Abstract 3560).
-- The Company announced that investigators dosed the first patient in a
multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-
targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470
in combination with several standard of care chemotherapy regimens,
including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel,
topotecan, and erlotinib. The trial is expected to enroll up to 105
patients at five study centers. The Phase 1b trial is an open label,
dose-escalation study designed to assess the safety and tolerability of
MP470 in combination with these standard of care chemotherapy regimens,
and to define the dose of MP470 to advance into Phase 2 combination
studies. Additionally, the Company will assess pharmacokinetic and
biomarker data from the study. The trial is open to chemotherapy naive
or treatment experienced patients with a variety of solid tumors
irrespective of previous lines of therapy.
Conference Call Information
SuperGen will host a conference call to discuss the results of the 2007
fourth quarter and annual financial results today at 1:30 p.m. PT / 4:30
p.m. ET. A live webcast of the conference call is accessible via the
investor relations section of
|SOURCE SuperGen Inc.|
Copyright©2008 PR Newswire.
All rights reserved